In conjunction with the prior case of NTRK1 inhibitor response in JXG, the current report of a response in an adult with XGs gives further evidence that targeted therapy may be beneficial for patients with XG across multiple ages and clinical presentations, harboring NTRK1 fusions. Here, NTRK1 is linked to juvenile xanthogranuloma.